[Advantage of intravenous pulse therapy with calcitriol or maxacalcitol in dialysis patients with renal hyperparathyroidism]
- PMID: 15577114
[Advantage of intravenous pulse therapy with calcitriol or maxacalcitol in dialysis patients with renal hyperparathyroidism]
Abstract
In dialysis patients, deficiency of calcitriol down regulates vitamin D receptor (VDR) and decreases density of Ca sensing receptor, resulting right shift of set point of extra cellular Ca concentrations to release of parathyroid hormone. And then, renal hyperparathyroidism occurs and progresses. The purpose of pulse therapy with calcitriol or its analogue is elevating extra cellular calcitriol level up to supra physiological level, which up regulates VDR and shift the set point to left. The extra cellular calcitriol level after injection of calcitriol cannot compare with the level after oral administration of calcitriol at the same dose. The left shift of set point is investigated 4 weeks after intravenous pulse therapy with calcitriol or maxacalcitol, and degree of shift to the left depends on the single dose of these medicines. There is another advantage of intravenous pulse therapy, which takes no account of drug compliance or existence of malabsorption of lipid soluble vitamins.
Similar articles
-
[Serum calcium concentration and the safety of vitamin D therapy].Clin Calcium. 2004 Sep;14(9):79-82. Clin Calcium. 2004. PMID: 15577116 Review. Japanese.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
[Vitamin D therapy in predialysis renal failure].Clin Calcium. 2004 Sep;14(9):73-7. Clin Calcium. 2004. PMID: 15577115 Review. Japanese.
-
Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.Nephrology (Carlton). 2011 Mar;16(3):277-84. doi: 10.1111/j.1440-1797.2010.01398.x. Nephrology (Carlton). 2011. PMID: 21342321 Clinical Trial.
-
Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.Clin Exp Nephrol. 2004 Jun;8(2):134-8. doi: 10.1007/s10157-004-0283-1. Clin Exp Nephrol. 2004. PMID: 15235930 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical